Related Experiment Video
Updated: Jun 22, 2026
Working with Auditory HEI-OC1 Cells
Published on: September 3, 2016
Cytotoxic effects of 2-methoxyestradiol in the hepatocellular carcinoma cell line HepG2
Reem N Abou El Naga1, Ebtehal El-Demerdash, Samar S Youssef
1Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
Aim:
The study was designed to examine the potential cytotoxicity of 2-methoxyestradiol (2ME2), a natural 17beta-estradiol metabolite, in hepatocellular carcinoma and the possible underlying mechanisms for this cytotoxicity.
Methods:
The cell line HepG2 was treated with different concentrations of 2ME2 for 48 and 72 h.
Results:
Using the sulforhodamine B assay, HepG2 was sensitive to the cytotoxic effect of 2ME2. 2ME2 induced cell arrest at the G(2)/M phase and a significant high percentage of apoptotic cells compared to the control group. Also, 2ME2 induced a significant increase in caspase 9 enzymatic activity after 48 and 72 h of treatment compared with control values. The DNA laddering was observed only in cells treated for 72 h. Furthermore, 2ME2 induced a significant decrease in the expression levels of vascular endothelial growth factor (VEGF) gene compared to the control values.
Conclusion:
2ME2 exerts cytotoxic activity in the HepG2 cell line by preferential cell blocking at the G(2)/M phase as well as induction of apoptosis as evidenced by increased caspase 9 enzymatic activity and observed DNA laddering in 2ME2-treated HepG2 cells. In addition, a reduction in hypervascularity is an important postulated mechanism as indicated by the significant reduction in the expression of VGEF, one of the most important angiogenic factors.
Insights
2-methoxyestradiol (2ME2) shows cytotoxicity in hepatocellular carcinoma cells by halting cell division and inducing apoptosis. This natural metabolite also reduces vascular endothelial growth factor (VEGF), potentially inhibiting tumor growth.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Hepatocellular carcinoma (HCC) is a significant global health concern.
- 2-methoxyestradiol (2ME2), a metabolite of 17beta-estradiol, has demonstrated anti-cancer properties.
- Understanding 2ME2's mechanisms in HCC is crucial for therapeutic development.
Purpose of the Study:
- To investigate the cytotoxic effects of 2-methoxyestradiol (2ME2) on hepatocellular carcinoma cells (HepG2).
- To elucidate the underlying mechanisms of 2ME2-induced cytotoxicity, including cell cycle effects, apoptosis induction, and impact on angiogenic factors.
Main Methods:
- HepG2 cells were treated with varying concentrations of 2ME2 for 48 and 72 hours.
- Cell viability was assessed using the sulforhodamine B assay.
- Cell cycle progression, apoptosis (caspase 9 activity, DNA laddering), and vascular endothelial growth factor (VEGF) gene expression were analyzed.
Main Results:
- 2ME2 exhibited significant cytotoxicity against HepG2 cells.
- Treatment with 2ME2 led to cell cycle arrest at the G(2)/M phase and induced apoptosis.
- Increased caspase 9 activity and DNA laddering were observed, confirming apoptosis induction.
- 2ME2 significantly reduced the expression of vascular endothelial growth factor (VEGF).
Conclusions:
- 2ME2 demonstrates potent cytotoxic activity in HepG2 cells.
- Mechanisms include G(2)/M phase cell cycle arrest and apoptosis induction via caspase 9 activation and DNA fragmentation.
- Downregulation of VEGF suggests a potential anti-angiogenic effect, contributing to its anti-cancer activity in HCC.
